Opinion

Video

Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please give an overview of treatment options for a patient who received 2L treatment with either CAR T-cell therapy or ASCT and has relapsed. 
      • What would be your treatment choice in the third line?
      • What key issues do you consider in your sequencing decisions?
      • Please discuss rationales for each:
    • Monoclonal antibody—tafasitamab?
    • ADC —loncastuximab, polatuzumab?
    • Would you go to CAR T after ASCT?
    • Bispecific antibody—epcoritamab or glofitamab?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content